

1 Health Supplements for Allergic Rhinitis: A Mixed-Methods

2 Systematic Review

3 J. Pellow
4 A. Nolte
5 A. Temane
6 E. M. Solomon

7 Abstract

8 Allergic rhinitis is a chronic inflammatory condition caused by an exaggerated response of
9 the immune system to common allergens. Most pharmacological therapies tend to be
10 palliative and in some cases are associated with adverse effects. There is a growing tendency
11 for people to self-medicate with health supplements as they are generally considered safe,
12 however clinical studies relating to their efficacy and safety are limited. This mixed-methods
13 systematic review aims to synthesise the available evidence relating to the treatment of
14 allergic rhinitis with a variety of health supplements. A total of 57 062 articles were derived
15 from searching seven online databases and evidence from 48 RCTs and 10 observational
16 studies were reviewed for methodological quality and risk of bias. No qualitative studies
17 meeting the inclusion criteria could be found, therefore only a quantitative review was
18 performed. Promising evidence for the following single supplements were found: apple
19 polyphenols, tomato extract, spirulina, chlorophyll c2, honey, conjugated linoleic acid, MSM,
20 isoquercitrin, vitamins C, D and E, as well as probiotics. Combination formulas may also be
21 beneficial, particularly specific probiotic complexes, a mixture of vitamin D₃, quercetin and
22 *Perilla frutescens*, as well as the combination of vitamin D₃ and *L. reuteri*. Owing to the
23 paucity of good quality evidence, recommendations pertaining to the use of health
24 supplements for allergic rhinitis should involve a shared decision-making process between
25 the healthcare provider and the patient, taking into account their efficacy, safety and cost.
26 Further good quality clinical studies and qualitative research would further our understanding
27 of the role these health supplements may play in future treatment protocols.

28
29 Keywords: health supplements, hay fever, allergic rhinitis, mixed-methods systematic review

30

31 1. Introduction

32 Allergic rhinitis is a common condition affecting around 20-30% of adults and up to 40% of
33 children worldwide. Characteristic symptoms of this condition include sneezing, rhinorrhoea,
34 nasal congestion and nasal pruritus. While not considered to be life threatening, this condition
35 has a significant impact on quality of life, and is linked to increased rates of absenteeism
36 from work and school, poor cognitive performance and rising healthcare costs. Conventional
37 treatment options include a variety of pharmacotherapy options, such as antihistamines,
38 corticosteroids and decongestants, which tend to be palliative and may be associated with
39 adverse effects. Specific immunotherapy (SIT) is considered a viable option in the long-term
40 management of allergic rhinitis, as it has a modulating effect on the immune system, however
41 it can be costly and time-consuming [1]. Health supplements have a nutritional physiological
42 effect on the body and may be used to supplement the person's diet; they include probiotics
43 and prebiotics, vitamins, minerals, amino acids, animal extracts, fatty acids, carotenoids,
44 bioflavonoids, and enzymes [2]. Easy access, relatively low cost, dissatisfaction with

45 conventional treatment and a desire to have control over their own healthcare are just some of
46 the reasons why people may choose to self-medicate with health supplements for their
47 chronic conditions [3,4]. This mixed-methods systematic review aims to provide a
48 comprehensive synthesis of the evidence relating to the treatment of allergic rhinitis with a
49 variety of health supplements.

50 **2. Materials and Methods**

51 2.1 Study Procedure

52 The mixed-methods systematic review was conducted according to the guidelines stated in
53 the Joanna Briggs Institute (JBI) Reviewers' Manual [5], and was accomplished using the
54 segregated methodology described by Sandelowski et al. [6], whereby individual, single
55 method reviews were conducted according to the type of evidence, and the findings then
56 combined in a 'mixed-methods' synthesis.

57

58 2.2 Inclusion and exclusion criteria

59 Published research evaluating the treatment of allergic rhinitis using health supplements were
60 considered eligible. Randomised controlled trials (RCTs), non-controlled trials (cohort, case
61 reports, case-control and case series studies) and qualitative studies were included. Clinical
62 studies comparing these interventions with placebo and/or conventional treatment were
63 considered. Studies where conventional medicines were allowed as 'rescue medication' were
64 also eligible for inclusion. Filters for date and language were not applied.

65

66 2.3 Types of participants

67 Participants of all age groups suffering from acute and/or chronic allergic rhinitis, whether
68 previously diagnosed or included based on presenting symptoms and history.

69

70 2.4 Types of interventions

71 Health supplements administered orally as either liquid, tablets, capsules or powders, or
72 through nasal inhalation, or intravenously, as either a single medicine or combination
73 product.

74

75 2.5 Outcome measures

76 Primary outcomes included: an improvement (severity and/or duration) of condition-specific
77 symptoms recorded in validated questionnaires, e.g. a symptom diary, visual analogue scales
78 (VAS), quality of life (QoL) scales, or individual symptom scores. Secondary outcomes
79 included: adverse events/aggravations requiring conventional 'rescue' medication (frequency
80 and quantity), and objective measures (peak nasal inspiratory flow rate (PNIF), the
81 appearance of nasal mucosa, immunoglobulin E (IgE) levels and other allergy and
82 inflammatory serum or nasal markers).

83

84 2.6 Sources of information

85 Published journal articles were sourced from seven online databases, namely PubMed,
86 Science Direct, Springer Link, Scopus, Academic Search Complete, MEDLINE, and
87 CINAHL. A final search update was performed on the 1st of December 2018.

88

89 2.7 Search strategy

90 The search strategy included free text and MeSH terms, and combinations of these (A + B)
91 were used to conduct the online search (Table 1). Lastly, additional studies were identified
92 from the reference lists of previously found articles.

93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142

2.8 Assessment of methodological quality

After duplicate studies were excluded, potentially relevant studies were identified based on their title and abstract. Full-text articles were assessed independently by two reviewers for eligibility, methodological quality, reliability and validity prior to inclusion into the review using the Mixed-Methods Appraisal Tool (MMAT). The MMAT consists of five sections, each relating to a specific study type (qualitative, RCTs, non-randomised studies, descriptive and mixed-methods studies). Each study was rated using descriptors and the criteria used to determine the score varies by design. The overall methodological quality score is calculated as a percentage [7]. Risk of bias was assessed in RCTs by means of the Cochrane Collaboration's tool [8]. The risk of bias tool covers six domains of bias, namely selection bias, performance bias, detection bias, attrition bias, reporting bias, and 'other' sources of bias. Within each domain, the risk of bias was rated as low, high or unclear. The RTI item bank was used to assess the quality of observational studies (case-control, case series/reports and cohort studies), and consists of 13 items that assess the risk of bias and confounding [9]. In order to establish confidence in the findings of the qualitative studies, the ConQual approach was utilised, which assesses quality based on the dependability and credibility of the findings [10].

2.9 Data extraction and synthesis

Data extraction forms [5, 11] were used to systematically extract study data, including the year of publication, author, setting, population/sample, the aim, study design/methodology, analysis, findings, limitations and conclusions. Information on outcome measures from quantitative studies and the author-derived themes from qualitative studies were extracted. A mixed-methods synthesis was conducted, where all studies were first synthesised according to their design (that is, qualitative versus quantitative), followed by an overarching synthesis across methodologies [11]. For the quantitative synthesis, the number and quality of studies regarding each condition were assessed, and common associations between studies were summarised as themes. The data were collected and graphically represented via tables. For the qualitative studies, a thematic synthesis was conducted, which involved an iterative process of the coding of text; the development of descriptive themes; and the generation of analytical themes which formed the conclusions. Finally, an aggregative mixed-methods synthesis was conducted whereby the quantitative synthesis was converted into qualitative themes, and these were combined with the findings of the initial qualitative synthesis [5].

3. Results

A total of 57 062 articles were derived from the search strategy (Table 2), and after duplicate records were removed and the articles evaluated for relevance, 48 RCTs and 10 observational studies were included in the review (Figure 1). No qualitative studies meeting the inclusion criteria could be found, therefore only the quantitative review was conducted.

The studies were methodologically heterogeneous, making use of a variety of means of implementing treatment strategies and assessing clinical outcomes. The results of these studies are summarised in Table 3 and the MMAT and risk of bias results are presented in Tables 4 and 5. The majority of these studies investigated the effects of single health supplement preparations, while combination formulas were investigated in nine studies. Fourteen studies received a 100% MMAT rating, indicating good methodological quality. While eight RCTS and two observational studies received a high risk of bias rating, a low

143 risk of bias rating was awarded to six RCTs and five observational studies. The remaining
144 studies were deemed to have an unclear risk of bias. Rater agreement was 85.1% between the
145 two reviewers, and a third reviewer was consulted when necessary to resolve disagreements.
146

147 3.1 Synthesis of related studies

148 Apple polyphenols

149 Apples are a rich source of polyphenols, most notably flavan-3-ols, hydroxycinnamic acids,
150 flavonols, dihydrochalcones and anthocyanidins. Apple polyphenols have various
151 physiological functions and pre-clinical studies have demonstrated its anti-allergic effects,
152 primarily through its ability to inhibit the release of histamine from mast cells and basophils
153 [13, 70, 71]. Enomoto et al. [12] conducted a four-week RCT to investigate the effect of a
154 drink containing apple polyphenols (50mg or 200mg daily) on the clinical symptoms of
155 patients with persistent allergic rhinitis. Significant improvements in nasal symptoms and
156 signs occurred, particularly sneezing attacks, nasal discharge and swelling of the nasal
157 turbinates. Only minor adverse effects were noted. The study by Kishi et al. [13] further
158 supports these findings. In this study, patients with Japanese cedar pollinosis who consumed
159 500mg of apple polyphenols before and during the pollen season were shown to have a
160 significant reduction in sneezing attacks.

161 Chlorophyll c2

162 *Sargassum horneri* (*S. horneri*) is a brown macroalgae that is a rich source in the chlorophyll
163 derivative, chlorophyll c2, as well as other active compounds such as polyphenols,
164 flavonoids, terpenoids, sterols, and sulfated polysaccharides. These compounds exhibit
165 diverse biological activities particularly anti-allergic, anti-inflammatory and antioxidant
166 effects [72]. Pre-clinical studies have demonstrated that *S. horneri* inhibits degranulation of
167 mast cells and basophils and reduces nasal symptoms in allergy-induced mice [73]; however
168 human clinical studies are limited. Fujiwara et al. [14] conducted a twelve-week RCT which
169 showed that use of chlorophyll c2 extract significantly reduces the need for ‘rescue’
170 medications such as antihistamines, in adults with allergic rhinitis. Although this study
171 received a high risk of bias rating due to a high attrition rate, it received a low rating in all
172 other domains.

173 Conjugated linoleic acid (CLA)

174 CLAs are naturally occurring fatty acids derived from fatty tissues of ruminant animals. Most
175 commercially available CLAs are however produced by the alkaline isomerization of plant
176 oils, such as sunflower oil, and tend to contain a mixture of 9- and 10-CLAs as well as other
177 CLA isomers. Animal studies have demonstrated that CLA has immune-modulating effects,
178 with the ability to affect both humoral and cellular immune responses, indicating that it may
179 be of benefit in allergic conditions [74]. Only one clinical study could be found relating to its
180 use for allergic rhinitis, which demonstrated that consuming CLA before and during the birch
181 pollen season improves sneezing and induces a feeling of wellbeing in patients. It also
182 appears to produce modest anti-inflammatory effects, reducing specific inflammatory and
183 allergy markers [15].

184

185 Honey

186 Honey has been used as a medicine since ancient times, and remains a popular food
187 worldwide. Its nutritional composition is affected by several factors such as floral source,
188 geographical location and season; however its main constituents include sugars, vitamins,

189 minerals, amino acids, proteins, enzymes, organic acids, volatile substances, and
190 polyphenols. Honey's many health properties include antioxidant, anti-inflammatory and
191 immune-modulating effects [75], however there is contradictory evidence regarding its use
192 for the treatment of allergic rhinitis. Rajan et al. [17] showed that consuming one tablespoon
193 of either unpasteurised or pasteurised honey daily was not beneficial in reducing nasal
194 symptoms, while more recently Asha'ari et al. [16] demonstrated that honey actually further
195 improves allergic rhinitis symptoms when used as an adjunct to loratadine rather than the use
196 of the antihistamine alone. Also, Saarinen et al. [18] showed that patients with birch pollen
197 allergy who consumed honey containing birch pollen prior to the onset of the pollen season,
198 had positive clinical changes, namely a significant improvement in symptoms and reduction
199 in the use of antihistamines. Both Rajan et al [17] and Saarinen et al. [18] received a high risk
200 of bias rating; the former due to a high attrition rate and the latter as it was a single-blinded
201 trial design.

202

203 Isoquercitrin

204 Quercetin supplements are widely used for their various health benefits and have been known
205 to have anti-inflammatory and anti-allergic properties. Despite its poor bioavailability, pre-
206 clinical studies have shown that this flavonoid has the ability to suppress mast cell activation,
207 inhibiting the release of several inflammatory and allergy-related chemical mediators, such as
208 histamine, leukotrienes and prostaglandins. Quercetin glucosides such as isoquercitrin have
209 been shown to exhibit similar therapeutic effects *in vivo* as quercetin itself, and appear to
210 have better bioavailability [76]. Both Hirano et al. [19] and Kawai et al. [20] performed
211 clinical studies assessing the effect of enzymatically modified isoquercitrin on patients with
212 Japanese cedar pollinosis. Significant improvements in ocular symptoms and certain
213 inflammatory markers were found in both studies, however little difference in nasal
214 symptoms occurred.

215 Methylsulfonylmethane (MSM)

216 MSM is a naturally occurring organosulfur compound whose anti-inflammatory properties
217 have been validated in both *in vitro* and *in vivo* studies. MSM is well-tolerated in dosages of
218 up to 4g a day in adults, with few adverse effects being reported [77]. Clinical studies relating
219 to its efficacy for allergic rhinitis are however limited. Barrager et al. [21] conducted a multi-
220 centre observational study which showed that use of 2,6g daily for one month significantly
221 reduces symptoms of seasonal allergic rhinitis, while the clinical trial by Hewlings and
222 Kalman [22] demonstrated that a daily dose of 3g for two weeks appears most effective in
223 relieving rhinitis symptoms and nasal obstruction. The study by Barrager et al. [21] received
224 100% rating on the MMAT and a low risk of bias rating.

225 Probiotics

226 Commercially available probiotics are sold worldwide and usually contain one or more
227 beneficial bacterial genera, such as *Lactobacillus*, *Bifidobacteria* or *Bacillus*; yeast strains
228 such as those of the *Saccharomyces* genus have also demonstrated health promoting effects.
229 Probiotic micro-organisms play a significant role in balancing the gut microbiome, which in
230 turn promotes immunological tolerance in allergic-related conditions [78]. Various different
231 types of probiotics have been investigated as a treatment option for allergic rhinitis, and will
232 be discussed according to bacterial genus.

233 *Bacillus*: The addition of *Bacillus clausii* (*B. clausii*) to antihistamine treatment was shown
234 to significantly reduce nasal eosinophils and the need for antihistamines in children [24].
235

236 *Bifidobacteria*: Use of *Bifidobacterium longum* (*B. longum*) strain BB536 was shown to
237 improve ocular symptoms and reduce the need for ‘rescue’ medication in patients with
238 Japanese cedar pollinosis in three separate trials [51-53], one of which received a low risk of
239 bias rating [51]. Another study showed that the probiotic *B. lactis* NCC2818 significantly
240 lowers nasal symptom scores, IL-5 and IL-13, as well as percentages of activated CD63
241 expressing basophils in patients with seasonal allergic rhinitis [45].

242 *Clostridium*: In a twelve-month RCT, six-month use of *Clostridium butyricum* (*C. butyricum*)
243 was found to enhance the efficacy of specific immunotherapy (SIT) for house dust mite-
244 sensitive patients, reducing nasal symptoms, the need for ‘rescue’ medication, and
245 modulating serum allergy markers. This effect was maintained in the six-month observation
246 period [54].

247 *Enterococcus*: In one good quality observational study with a low risk of bias, lysed
248 *Enterococcus faecalis* (*E. faecalis*) FK-23 use significantly reduced nasal symptoms, signs
249 and serum eosinophils in house dust mite-sensitive patients [44].
250

251 *Escherichia*: One RCT showed that use of *Escherichia coli* strain Nissle 1917 for six months
252 was not superior to placebo in relieving symptoms of allergic rhinitis [27].
253

254 *Lactococcus*: Supplementation with *Lactococcus lactis* subsp. cremoris YRC3780 (1g, 0.1g
255 or 0.01g) for a period of twelve weeks has a tendency to decrease the need for ‘rescue’
256 medication and thymus- and activation-regulated chemokine (TARC) levels in patients with
257 birch pollinosis [47].
258

259 *Lactobacillus*: Several studies relating to the use of *Lactobacillus* (*L.*) strains have been
260 conducted, many with positive findings. In one study, consumption of milk fermented with *L.*
261 *acidophilus* L-92 was shown to improve the symptoms of Japanese cedar pollinosis and
262 reduce the need for ‘rescue’ medications [29], while *L. johnsonii* EM1 use in combination
263 with levocetirizine proved more effective than the antihistamine alone in relieving symptoms
264 in children; this amelioration continued for at least three months after discontinuation of the
265 probiotic [36]. Both these studies received a high risk of bias rating due to insufficient
266 blinding in their study designs. Seven studies investigated the effects of *L. paracasei*
267 specifically. In 2004, Wang et al. [48] reported that children sensitised to house dust mite
268 who consumed yogurt containing live *L. paracasei*-33 (LP-33) for one month had a
269 significantly improved quality of life. Similar results were shown for heat-killed LP-33 [42].

270 Costa et al. [25] showed that LP-33 use for seven weeks produced a significant improvement
271 in quality of life and ocular symptoms in patients sensitive to grass pollen, who were using an
272 oral antihistamine (loratadine), while the *L. paracasei* strain KW3110 also appears to have
273 some benefits in improving rhinitis control in patients allergic to cedar pollen [55]. In another
274 study, four-week consumption of *L. paracasei* ST11-fermented milk resulted in significantly
275 lower nasal congestion and pruritus scores after a nasal provocation test, and down-regulated
276 IL-5 and allergen-specific IgG4 in grass pollen-sensitive patients [49].
277

278 Nagata et al. [38] performed two six-week RCTs on female students allergic to Japanese
279 cedar pollen and found that *L. plantarum* LP14 taken daily significantly improves ocular
280 symptoms and induces the gene expression of Th1-type cytokines. Similarly, consumption of
281 *L. plantarum* YIT 0132 also significantly improves symptoms, quality of life and reduces
282 eosinophils in patients with Japanese cedar pollinosis [28]. This study received a high risk of
283 bias due to its single-blinded design. Lastly, one good quality RCT showed that *L. salivarius*
284 PM-A0006 taken for twelve weeks significantly reduces allergic rhinitis symptoms and
285 ‘rescue’ medication use in children with perennial allergic rhinitis [34].
286

287 Despite these positive results, several *Lactobacillus*-related studies did not show statistically
288 significant results. Use of *L. casei* Shirota failed to provide clinical benefit to seasonal
289 allergic rhinitis sufferers [30, 46], while *L. rhamnosus* use for twelve weeks does not appear
290 to further improve symptoms in children [31]. Lastly, *L. paracasei* strain NCC 2461 and
291 HF.A00232 do not provide additional therapeutic benefits to patients using conventional
292 treatment, however the latter strain may continue to induce improvements in symptoms after
293 discontinuation of antihistamine therapy [35, 39].
294

295 *Tetragenococcus*: Consumption of *Tetragenococcus halophilus* (*T. halophilus*) Th221 in a
296 daily dose of either 20.4mg or 60mg for eight weeks does not appear to produce a significant
297 therapeutic benefit, however participants receiving the higher dose in this trial showed trends
298 for improvement over time [40].

299 *Probiotic complex*: Probiotic supplements found on the market typically consist of a
300 combination of two or more bacterial genera or strains. A number of good quality, low risk
301 of bias studies relating to specific complexes were found. The probiotic complex containing
302 *L. acidophilus* NCFM (ATCC 700396) and *B. lactis* BI-04 (ATCC SD5219) was shown to
303 reduce nasal eosinophilia and modulate rhinitis symptoms [41]. Perrin et al. [43] however
304 found that use of *L. paracasei* NCC2461 on its own produced superior results to a blend of *L.*
305 *acidophilus* ATCC SD5221 and *B. lactis* ATCC SD5219 in a crossover trial; while no effect
306 was observed on nasal congestion, four weeks of treatment with NCC2461 was shown to
307 significantly decrease nasal pruritus, reduce nasal leukocytes and IL-5, and enhance serum
308 IL-5, IL-13 and IL-10 levels. In the RCT by Dennis-Wall et al. [26], daily use of a complex
309 of *L. gasseri* KS-13, *B. bifidum* G9-1, and *B. longum* MM-2 for eight weeks was shown to
310 significantly improve rhinoconjunctivitis-specific quality of life during the allergy season,
311 while the combination of *B. bifidum* W23, *L. acidophilus* W55, *L. casei* W56, *L. salivarius*
312 W57, and *L. lactis* W58 was shown to significantly improve symptoms and quality of life
313 when taken over a two-month period [50]. In a RCT by Kawase et al. [32], the complex of
314 *Lactobacillus* GG and *L. gasseri* TMC0356 taken daily for ten weeks, significantly improved
315 nasal obstruction, reduced the need for ‘rescue’ medication and modulated cytokine
316 production.
317

318 In another RCT, consumption of yoghurt fortified with *L. rhamnosus* GR-1 and *B.*
319 *adolescentis* 70007-05 had little clinical benefit; it did however produce potentially desirable
320 effects on the cytokine profile [33]. In a four-month observational study, use of dietary
321 yoghurt containing *L. acidophilus* and *Bifidobacterium* improved muco-ciliary transport time
322 and symptom scores, highlighting its potential benefits for allergic rhinitis sufferers [23]. The
323 latter two studies received an unclear risk of bias due to insufficient methodological
324 reporting.

325 326 Spirulina

327 Spirulina (*Arthrospira platensis*) is a microscopic filamentous cyanobacterium extensively
328 consumed as a health supplement for its nutritional content and health promoting benefits. It
329 contains essential amino acids, minerals, essential fatty acids, vitamins, and carotenoids.
330 Spirulina has been shown to modulate the immune system by inhibiting the release of
331 histamine from mast cells and lowering cytokine IL-4 levels, however there is a paucity of
332 human clinical trials [79, 80]. In a six-month RCT by Cingi et al. [56], daily consumption of
333 spirulina tablets for six months was shown to improve both symptoms and signs of allergic
334 rhinitis, with positive patient feedback received regarding perceived effectiveness and
335 satisfaction with treatment.

336 Tomato extract

337 The tomato fruit of the Solanaceae family is a popular food source worldwide. It is rich in
338 bioactive compounds, most notably carotenoids (lycopene, β -carotene and lutein), vitamins
339 and phenolic compounds (flavonoids, phenolic acids and tannins), to which its antioxidant
340 and anti-inflammatory properties are attributed [81]. Studies on the use of tomato extract in
341 the treatment of allergic rhinitis are limited however promising results were found in one
342 RCT, which showed its potential to significantly decrease nasal symptoms and improve
343 quality of life of patients allergic to house dust mite [57].

344 Vitamin C

345 Vitamin C, also known as ascorbic acid, is a water-soluble antioxidant with immune-
346 modulating effects. Allergy sufferers tend to produce a variety of reactive oxygen species
347 (ROS) from the cells lining the airways, resulting in a weakened antioxidant defence
348 mechanism and pathological inflammatory changes of the nasal mucosa. These changes
349 include lipid peroxidation, heightened sensitivity and reactivity of the mucosa, production of
350 chemoattractant molecules, and increased vascular permeability [82]. It is therefore possible
351 that supplementing with antioxidants may provide clinical benefits to allergic rhinitis
352 sufferers, and epidemiological studies have shown that increased intake of vitamin C is
353 associated with fewer symptoms in children [83, 84]. Case studies conducted in the 1940s
354 provided conflicting anecdotal evidence regarding the use of oral vitamin C in the treatment
355 of allergic rhinitis [58, 59, 61], two of which received a high risk of bias rating as they failed
356 to report on adverse effects [58, 59]. More recently, an RCT conducted by Podoshin et al.
357 [60] showed that two-week use of nasal applications of ascorbic acid reduces nasal oedema,
358 mucous secretions and nasal obstruction, while Vollbracht et al. [62] demonstrated that high
359 doses of intravenous vitamin C had positive clinical benefits for patients with both acute and
360 chronic allergic rhinitis. The study by Vollbracht et al. [62] scored 100% on the MMAT and
361 was deemed to have a low risk of bias.

362 363 Vitamin D

364 Vitamin D deficiency is common worldwide and may be an important environmental risk
365 factor in the development of allergic disease. Epidemiological studies have found an
366 association between low serum vitamin D levels and the incidence of allergic disorders [85].
367 Vitamin D exists in two main forms, namely ergocalciferol (vitamin D2) and cholecalciferol
368 (vitamin D3). It exerts its immunomodulatory effects through vitamin D receptors which are
369 found on a variety of immune cells such as B and T cells, dendrites and macrophages,
370 thereby influencing the allergy-related inflammatory response [86]. Clinical evidence of its
371 use for allergic rhinitis is unfortunately limited. Jerzyńska et al. [63] demonstrated the results
372 of a RCT on the effects of five-months of vitamin D supplementation in children with grass
373 pollen-related allergic rhinitis, and found a significant reduction in symptoms, the need for
374 'rescue' medication, as well as an immune-modulating effect. Although the study by
375 Jerzyńska et al. [63] was of good methodological quality, it received a high risk of bias rating
376 due to its high attrition rate. High dosages of vitamin D given orally have been demonstrated
377 to enhance symptomatic relief in patients with asthma and allergic rhinitis undergoing pollen
378 specific immunotherapy [65]. Furthermore, the RCT by Malik et al. [64] showed that allergic
379 rhinitis sufferers deficient in vitamin D who receive supplementation have a highly
380 significant improvement in nasal symptoms.

381
382 Two health supplement complexes containing vitamin D have been studied. A proprietary
383 complex containing vitamin D3, as well as quercetin and the medicinal plant *Perilla*
384 *frutescens*, was shown to significantly reduce allergic rhinitis symptoms when used for one
385 month in a good quality observational study. Use of the complex decreased the need for
386 'rescue' medication [66]. *Perilla frutescens*, of the Lamiaceae family, is a rich source of anti-
387 allergic and anti-inflammatory constituents, including rosmarinic acid and quercetin, as well
388 as omega-3, -6, and -9 polyunsaturated fatty acids [87]. The benefits of quercetin for allergic
389 conditions have been previously mentioned. In a single-blinded, non-randomised controlled
390 study by Ciprandi and Varrichio [67], adjunctive use of a food supplement containing
391 vitamin D3 800iu and *Lactobacillus reuteri* (*L. reuteri*) DSM 17938) for one month, together
392 with specific immunotherapy for Parietaria pollinosis, improved the perceived effectiveness
393 of SIT by reducing symptom severity and antihistamine use.

394 Vitamin E

395 The vitamin E family refers to eight distinct isoforms, namely four tocopherols and four
396 tocotrienols. Vitamin E plays a significant role in immune system functioning however there
397 are currently conflicting reports regarding its role in the treatment of allergic diseases [88,
398 89]. A clinical study by Shahar et al. [69] reported that supplementation with vitamin E in
399 addition to conventional anti-allergy medication for two months, further improves nasal
400 symptoms in patients with seasonal allergic rhinitis, while Montaña Velázquez et al. [68]
401 demonstrated no clinical benefits for perennial allergic rhinitis sufferers taking this
402 supplement.

403

404 4. Discussion

405 Mixed-method systematic reviews are designed to address the issue of synthesising evidence
406 related to a particular topic and provide a reliable basis for clinical decision-making as they
407 are replicable, reduce bias and resolve controversy between conflicting findings [8, 11]. Very
408 few reviews on the use of health supplements for the treatment of allergic rhinitis have been
409 previously conducted. In one review, Tian & Cheng [85] found clinical evidence supporting
410 low serum vitamin D levels with an increased risk for developing allergic rhinitis, however

411 recommended further research be conducted with regards to using vitamin D as a treatment
412 option. Yang et al. [90] concluded that probiotics may play an important role in the
413 prevention and treatment of allergic rhinitis, the benefits of which are dependent on the type
414 of bacterium administered and the dosage regimen used. Newman [91] conducted a
415 systematic review on the use of unpasteurised honey in the treatment of allergic rhinitis, and
416 found contradictory results from the two studies that were reviewed; therefore, no definitive
417 recommendations could be made.

418
419 Health supplements are widely available in pharmacies, health shops, and other retail outlets,
420 and are usually brought to market without the foundation of clinical trials. There is a growing
421 tendency for people to self-medicate with these products, seldom seeking advice from a
422 qualified healthcare practitioner. Although the intake of dietary supplements is generally
423 considered safe, the potential risk when used inappropriately is significant, as they can exert a
424 physiological and pharmacological effect [92]. This current review found promising evidence
425 for the use of several health supplements; namely apple polyphenols, tomato extract,
426 spirulina, chlorophyll c2, honey, CLA, MSM, isoquercitrin, vitamins C, D and E, as well as
427 various probiotics. Of these, probiotics appears to be the most widely studied with several
428 different micro-organism strains showing promising results, such as *B. clausii*, *B. longum*
429 BB536, *B. lactis* NCC2818, *C. butyricum*, *E. faecalis*, *Lactococcus lactis* subsp. cremoris
430 YRC3780, *L. acidophilus* L-91, *L. johnsonii* EM1, and several *L. paracasei* strains, *L.*
431 *plantarum* LP14 and *L. salivarius* PM-A0006. Specific health supplement combinations also
432 may be beneficial, however only a few studies relating to these could be found.

433
434
435 One of the main limitations of this review is the limited evidence available for each
436 supplement. Also, of those studies that were reviewed, many made use of a small sample
437 size, which may have had an impact on the statistical validity of the findings. Another major
438 challenge encountered was the difficulty in accurately rating the methodological quality and
439 risk of bias of included studies, owing to insufficient reporting in many of the research
440 articles reviewed. This was more evident with older publications, and led to a high number of
441 studies being rated as having an unclear or high risk of bias. There are a number of validated
442 checklists available for authors to use when publishing the results of their studies, and these
443 are helpful to ensure standardisation in reporting. Examples of these include the Consolidated
444 Standards of Reporting Trials (CONSORT) for randomised controlled trials [93]; the
445 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement
446 for epidemiological studies [94]; and the Guidelines for Conducting and Reporting Mixed
447 Research for Counselor Researchers for mixed-methods designs [95].

448
449 Qualitative research forms a vital cornerstone in informing healthcare practices as it provides
450 valuable insights into patients' experiences, values and healthcare needs [96]. There were
451 unfortunately very few eligible qualitative studies regarding the use of health supplements for
452 allergic rhinitis, and this highlights a research gap that requires further investigation.

453
454 On a positive note, very few adverse effects of the evaluated health supplements were
455 reported overall, and these interventions could possibly be considered as low-risk treatment
456 options if used appropriately. Ideally, recommendations pertaining to the use of these
457 interventions should involve a shared decision-making process between the healthcare
458 provider and the patient, and potential efficacy, risks and benefits, and financial implications
459 of their use should be taken into account. Further large-scale studies are warranted to fully
460 understand the role health supplements may play in managing this condition.

461

462 **5. Conclusion**

463 This mixed-methods systematic review provides a complete and fair representation of the
464 currently available evidence derived from 48 RCTs and 10 observational studies on the use of
465 various health supplements in the treatment of allergic rhinitis. A number of individual health
466 supplements were identified as having a beneficial effect on this condition, such as
467 probiotics, CLA, MSM, spirulina, chlorophyll c2, honey, plant-based extracts (apple
468 polyphenols, tomatoes and isoquercetrin) and vitamins C, D and E. Various health
469 supplement combinations were also investigated and found to have promising results,
470 particularly specific probiotic complexes, a mixture of vitamin D₃, quercetin and *Perilla*
471 *frutescens*, as well as the combination of vitamin D₃ and *L. reuteri*. Future research on the use
472 of these interventions is warranted in order to verify their efficacy and safety as potential
473 treatment options to address patients' needs and preferences.

474 **Data Availability**

475 The data that supports the findings of this study is available from the University of
476 Johannesburg but restrictions apply to the availability of this data, which was used under
477 license for the current study, and so is not publicly available. Data is however available from
478 the authors upon reasonable request and with permission from the University of
479 Johannesburg.

480 **Conflicts of Interest**

481 The authors declare that there is no conflict of interest regarding the publication of this paper.

482 **Funding Statement**

483 This work was financed and supported by the University of Johannesburg.

484 **Acknowledgments**

485 The authors would like to thank the University of Johannesburg for the support of this
486 research, and specifically Antonet Sandelowitz in the library postgraduate centre for her
487 assistance in obtaining the data.

488 **References**

489 [1] F. C. L. Hoyte and H. S. Nelson, "Recent advances in allergic rhinitis," *F1000Research*,
490 7: F1000 Faculty Rev-1333, 2018. doi:10.12688/f1000research.15367.1.

491 [2] MCC (Medicines Control Council), "Complementary medicine- discipline-specific safety
492 and efficacy," Available from:
493 http://www.mccza.com/documents/8b57b09c7.01_CM_s_SE_DS_Jun16_v3.pdf. Accessed
494 16/10/2019.

495 [3] S. Eardley, F. L. Bishop, P. Prescott, et al., "A systematic literature review of
496 complementary and alternative medicine prevalence in EU," *Forschende*
497 *Komplementärmedizin*, vol. 19, Supplement 2, pp. 18-28, 2012.

- 498 [4] N. Corp, J. L. Jordan, and P. R. Croft, "Justifications for using complementary and
499 alternative medicine reported by persons with musculoskeletal conditions: A narrative
500 literature synthesis," *PloS one*, vol. 13, no. 7, e0200879, 2018,
501 doi:10.1371/journal.pone.0200879.
- 502 [5] The Joanna Briggs Institute, "Joanna Briggs Institute Reviewers' Manual: 2014 edition.
503 Methodology for JBI mixed methods systematic reviews," The University of Adelaide,
504 Australia, 2014, [http://joannabriggs.org/assets/docs/approach/Levels-of-Evidence-
505 SupportingDocuments.pdf](http://joannabriggs.org/assets/docs/approach/Levels-of-Evidence-SupportingDocuments.pdf).
- 506 [6] M. Sandelowski, C. I. Voils, J. and Barroso, J, "Defining and designing mixed research
507 synthesis studies," *Research in the Schools*, vol. 13, p. 29, 2006.
- 508 [7] P. Pluye, E. Robert, M. Cargo et al., "Proposal: A mixed methods appraisal tool for
509 systematic mixed studies reviews," 2011, Available from:
510 [http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/84371689/MMAT%202011
511 1%20criteria%20and%20tutorial%202011-06-29updated2014.08.21.pdf](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/84371689/MMAT%202011%20criteria%20and%20tutorial%202011-06-29updated2014.08.21.pdf).
- 512 [8] J. Higgins, S. Green, "Cochrane handbook for systematic reviews of interventions. Part 2:
513 general methods for Cochrane reviews," 2011, Available from:
514 <http://handbook.cochrane.org/>.
- 515 [9] M. Viswanathan, N. D. Berkman, D. M. Dryden, and L. Hartling, "Assessing Risk of Bias
516 and Confounding in Observational Studies of Interventions or Exposures: Further
517 Development of the RTI Item Bank," Rockville (MD): Agency for Healthcare Research and
518 Quality (US); 2013 Aug. Report No.: 13-EHC106-EF. AHRQ Methods for Effective Health
519 Care, 2013.
- 520 [10] The Joanna Briggs Institute, "Establishing confidence in qualitative evidence," 2017,
521 Available from: [https://health.adelaide.edu.au/jbi/current-students/resources/
522 establishing-confidence-in-qualitative-evidence-presentation-notes.pdf](https://health.adelaide.edu.au/jbi/current-students/resources/establishing-confidence-in-qualitative-evidence-presentation-notes.pdf).
- 523 [11] A. Pearson, H. White, F. Bath-Hextall, S. Salmond, J. Apostolo, and P. Kirkpatrick, "A
524 mixed-methods approach to systematic reviews," *International Journal of Evidence Based
525 Healthcare*, vol.13, issue 3, pp. 121-131, 2015.
- 526 [12] T. Enomoto, Y. Nagasako-Akazome, T. Kanda, M. Ikeda, and Y. Dake, "Clinical effects
527 of apple polyphenols on persistent allergic rhinitis: a randomized double-blind placebo-
528 controlled parallel arm study," *Journal of Investigational Allergology & Clinical
529 Immunology*, vol. 16, pp. 283-289, 2006.
- 530 [13] K. Kishi, M. Saito, T. Saito et al., "Clinical efficacy of apple polyphenol for treating
531 cedar pollinosis," *Bioscience, Biotechnology and Biochemistry*, vol. 69, no. 4, pp. 829-832,
532 2005, doi: 10.1271/bbb.69.829.
- 533 [14] T. Fujiwara, N. Nishida, J. Nota et al., "Efficacy of chlorophyll c2 for seasonal allergic
534 rhinitis: single-center double-blind randomized control trial," *European Archives of Oto-
535 Rhino-Laryngology*, vol. 273, no. 12, pp. 4289-4294, 2016.

- 536 [15] A. M. Turpeinen, N. Ylönen, E. von Willebrand, S. Basu, and A. Aro, “Immunological
537 and metabolic effects of cis-9, trans-11-conjugated linoleic acid in subjects with birch pollen
538 allergy,” *British Journal of Nutrition*, vol. 100, no. 1, pp. 112-119, 2008, doi:
539 10.1017/S0007114507886326.
- 540 [16] Z. A. Asha'ari, M. Z. Ahmad, W. S. Jihan, C. M. Che, and I. Leman, “Ingestion of honey
541 improves the symptoms of allergic rhinitis: evidence from a randomized placebo-controlled
542 trial in the East coast of Peninsular Malaysia,” *Annals of Saudi Medicine*, vol. 33, no. 5, pp.
543 469–475, 2013, doi:10.5144/0256-4947.2013.469.
- 544 [17] T. V. Rajan, H. Tennen, R. L. Lindquist, L. Cohen, and J. Clive, “Effect of ingestion of
545 honey on symptoms of rhinoconjunctivitis,” *Annals of Allergy, Asthma & Immunology*, vol.
546 88, no. 2, pp. 198-203, 2002.
- 547 [18] K. Saarinen, J. Jantunen, and T. Haahtela, “Birch pollen honey for birch pollen allergy--
548 a randomized controlled pilot study,” *International Archives of Allergy & Immunology*, vol.
549 155, no. 2, pp. 160-166, 2011, doi: 10.1159/000319821.
- 550 [19] T. Hirano, M. Kawai, J. Arimitsu et al., “Preventative effect of a flavonoid,
551 enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis,”
552 *Allergology International*, vol. 58, no. 3, pp. 373-382, 2009, doi: 10.2332/allergolint.08-OA-
553 0070.
- 554 [20] M. Kawai, T. Hirano, J. Arimitsu et al., “Effect of enzymatically modified isoquercitrin,
555 a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-
556 controlled trial,” *International Archives of Allergy & Immunology*, vol. 149, no. 4, pp. 359-
557 368, 2009, doi: 10.1159/000205582.
- 558 [21] E. Barrager, J. R. Veltmann Jr., A. G. Schauss, and R. N. Schiller, “A multicentered,
559 open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of
560 seasonal allergic rhinitis,” *Journal of Alternative & Complementary Medicine*, vol. 8, no. 2,
561 pp. 167-173, 2002.
- 562 [22] S. Hewlings and D. S. Kalman, “Evaluating the impacts of methylsulfonylmethane on
563 allergic rhinitis after a standard allergen challenge: randomized double-blind exploratory
564 study,” *JMIR Research Protocols*, vol. 7, no. 11, e11139, 2018, doi: 10.2196/11139.
- 565 [23] C. Aldinucci, L. Bellussi, G. Monciatti et al., “Effects of dietary yoghurt on
566 immunological and clinical parameters of rhinopathic patients,” *European Journal of Clinical
567 Nutrition*, vol. 56, pp. 1155–1161, 2002.
- 568 [24] G. Ciprandi, A. Vizzaccaro, I. Cirillo, and M. A. Tosca, “Bacillus clausii effects in
569 children with allergic rhinitis,” *Allergy*, vol. 60, no. 5, pp. 702-703, 2005, doi:
570 10.1111/j.1398-9995.2005.00722.x.
- 571 [25] D. J. Costa, P. Marteau, M. Amouyal, et al. “Efficacy and safety of the probiotic
572 Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-
573 controlled trial (GA2LEN Study),” *European Journal of Clinical Nutrition*, vol. 68, pp. 602–
574 607, 2014.

- 575 [26] J. C. Dennis-Wall, T. Culpepper, C. Nieves Jr., et al. "Probiotics (Lactobacillus gasseri
576 KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve
577 rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-
578 blind, placebo-controlled, randomized trial," *American Journal of Clinical Nutrition*, vol.
579 105, no. 3, pp. 758-767, 2017, doi: 10.3945/ajcn.116.140012.
- 580 [27] S. Dölle, J. Berg, C. Rasche, and M. Worm, "Tolerability and clinical outcome of
581 coseasonal treatment with Escherichia coli strain Nissle 1917 in grass pollen-allergic
582 subjects," *International Archives of Allergy & Immunology*, vol. 163, pp. 29–35, 2014, doi:
583 10.1159/000356328.
- 584 [28] N. Harima-Mizusawa, T. Iino, N. Onodera-Masuoka, et al. "Beneficial effects of citrus
585 juice fermented with Lactobacillus plantarum YIT 0132 on Japanese cedar pollinosis,"
586 *Bioscience of Microbiota and Food Health*, vol. 33, no.4, pp. 147-155, 2014, doi:
587 10.12938/bmfh.33.147.
- 588 [29] Y. Ishida, F. Nakamura, H. Kanzato, et al. "Effect of milk fermented with Lactobacillus
589 acidophilus strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized
590 placebo-controlled trial," *Bioscience, Biotechnology & Biochemistry*, vol. 69, no. 9, pp. 1652-
591 1660, 2005.
- 592 [30] K. Ivory, A. M. Wilson, P. Sankaran, et al. "Oral delivery of a probiotic induced changes
593 at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a
594 randomised clinical trial," *PLoS One*, vol. 8, no. 11, e78650, 2013, doi:
595 10.1371/journal.pone.0078650.
- 596 [31] R-H. Jan, C-J. Chen, L-K. Chen, S-H. Wen, and T-Y. Lin, "Is the effect of probiotics on
597 allergic rhinitis confined to Dermatophagoides farinae, Dermatophagoides pteronyssinus, or
598 dust-sensitive children? A randomized prospective double-blind controlled trial," *Tzu Chi
599 Medical Journal*, vol. 23, no. 2, pp. 51-54, 2011.
- 600 [32] M. Kawase, F. He, A. Kubota, et al. "Effect of fermented milk prepared with two
601 probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical
602 study," *International Journal of Food Microbiology*, vol. 128, no. 3, pp. 429-34, 2009, doi:
603 10.1016/j.ijfoodmicro.2008.09.017.
- 604 [33] T. Koyama, P. V. Kirjavainen, C. Fisher, et al. "Development and pilot evaluation of a
605 novel probiotic mixture for the management of seasonal allergic rhinitis," *Canadian Journal
606 of Microbiology*, vol. 56, no. 9, pp. 730-738, 2010, doi: 10.1139/w10-061.
607
- 608 [34] T. Y. Lin, C. J. Chen, L. K. Chen, S. H. Wen, and R. H. Jan, "Effect of probiotics on
609 allergic rhinitis in Df, Dp or dust-sensitive children: a randomized double blind controlled
610 trial". *Indian Pediatrics*, vol. 50, pp. 209–213, 2013.
611
- 612 [35] W. Y. Lin, L. S. Fu, H. K. Lin, C. Y. Shen, and Y. J. Chen, "Evaluation of the effect of
613 Lactobacillus paracasei (HF.A00232) in children (6-13 years old) with perennial allergic
614 rhinitis: a 12-week, double-blind, randomized, placebo-controlled study," *Pediatrics &
615 Neonatology*, vol. 55, no. 3, pp.181-188, 2014 doi: 10.1016/j.pedneo.2013.10.001.

- 616 [36] K-H. Lue, H-L. Sun, K-H. Lu, et al., “A trial of adding *Lactobacillus johnsonii* EM1 to
617 levocetirizine for treatment of perennial allergic rhinitis in children aged 7–12 years,”
618 *International Journal of Pediatric Otorhinolaryngology*, vol. 76, no.7, pp. 994-1001, 2012.
- 619 [37] M. Miraglia Del Giudice, C. Indolfi, M. Capasso, et al., “Bifidobacterium mixture (B
620 longum BB536, B infantis M-63, B breve M - 16V) treatment in children with seasonal
621 allergic rhinitis and intermittent asthma,” *Italian Journal of Pediatrics*, vol. 43, p. 25, 2017.
- 622 [38] Y. Nagata, M. Yoshida, H. Kitazawa, E. Araki, and T. Gomyo, “Improvements in
623 seasonal allergic disease with *Lactobacillus plantarum* No. 14,” *Bioscience, Biotechnology &*
624 *Biochemistry*, vol. 74, no. 9, pp. 1869-1877, 2010.
- 625 [39] C. Nembrini, A. Singh, C. A. De Castro, and A. M. S. Nutten, “Oral administration of
626 *Lactobacillus paracasei* NCC 2461 for the modulation of grass pollen allergic rhinitis: a
627 randomized, placebo-controlled study during the pollen season,” *Clinical and Translational*
628 *Allergy*, vol. 5, 2015, doi: 10.1186/s13601-015-0085-4.
- 629 [40] I. Nishimura, T. Igarashi, T. Enomoto, et al., “Clinical efficacy of halophilic lactic acid
630 bacterium *Tetragenococcus halophilus* Th221 from soy sauce moromi for perennial allergic
631 rhinitis,” *Allergology International*, vol. 58, no. 2, pp. 179-185, 2009, doi:
632 10.2332/allergolint.O-08-548.
- 633 [41] A. C. Ouweland, M. Nermes, M. C. Collado et al., “Specific probiotics alleviate allergic
634 rhinitis during the birch pollen season,” *World Journal of Gastroenterology*, vol. 15, no. 26,
635 pp. 3261–3268, 2009, doi: 10.3748/wjg.15.3261.
- 636 [42] G-C. Peng and C-H. Hsu, “The efficacy and safety of heat-killed *Lactobacillus paracasei*
637 for treatment of perennial allergic rhinitis induced by house-dust mite,” *Pediatric Allergy and*
638 *Immunology*, vol. 16, no. 5, pp. 433–438, 2005.
- 639 [43] Y. Perrin, S. Nutten, R. Audran et al., “Comparison of two oral probiotic preparations in
640 a randomized crossover trial highlights a potentially beneficial effect of *Lactobacillus*
641 *paracasei* NCC2461 in patients with allergic rhinitis,” *Clinical & Translational Allergy*, vol.
642 4, p. 1, 2014, doi: 10.1186/2045-7022-4-1.
- 643 [44] T. Shimada, L. Cheng, T. Enomoto et al., “Lysed *Enterococcus faecalis* FK-23 oral
644 administration reveals inverse association between tuberculin responses and clinical
645 manifestations in perennial allergic rhinitis: a pilot study,” *Journal of Investigative*
646 *Allergology & Clinical Immunology*, vol. 14, no. 3, pp. 187-192, 2004.
- 647 [45] A. Singh, F. Hacini-Rachinel, M. L. Gosoni et al., “Immune-modulatory effect of
648 probiotic *Bifidobacterium lactis* NCC2818 in individuals suffering from seasonal allergic
649 rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial,”
650 *European Journal of Clinical Nutrition*, vol. 67, no.2, pp. 161-167, 2013, doi:
651 10.1038/ejcn.2012.197.
- 652 [46] M. Tamura, T. Shikina, T. Morihana et al., “Effects of probiotics on allergic rhinitis
653 induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical
654 trial,” *International Archives of Allergy and Immunology*, vol. 143, no. 1, pp. 75–82, 2007.

- 655 [47] K. Uchida, H. Motoshima, N. Katano et al., “Effect of *Lactococcus lactis* subsp.
656 *cremoris* YRC3780 on birch pollinosis: a randomized, double-blind, placebo-controlled
657 clinical trial,” *Journal of Functional Foods*, vol. 43, pp.173-179, 2018.
- 658 [48] M. F. Wang, H. C. Lin, Y. Y. Wang, and C. H. Hsu, “Treatment of perennial allergic
659 rhinitis with lactic acid bacteria,” *Pediatric Allergy and Immunology*, vol. 15, no. 2, pp. 152–
660 158, 2004.
- 661 [49] J. Wassenberg, S. Nutten, R. Audran et al., “Effect of *Lactobacillus paracasei* ST11 on a
662 nasal provocation test with grass pollen in allergic rhinitis,” *Clinical & Experimental Allergy*,
663 vol. 41, pp. 565–573, 2011.
- 664 [50] A. M. Watts, A. J. Cox, P. K. Smith et al., “A specifically designed multispecies
665 probiotic supplement relieves seasonal allergic rhinitis symptoms,” *Journal of Alternative &
666 Complementary Medicine*; vol. 24, no. 8, pp. 833-840, 2018, doi: 10.1089/acm.2017.0342.
- 667 [51] J. Z. Xiao, S. Kondo, N. Yanagisawa et al., “Probiotics in the treatment of Japanese
668 cedar pollinosis: a double-blind placebo-controlled trial,” *Clinical & Experimental Allergy*,
669 vol. 36, no. 11, pp. 1425-35, 2006.
- 670 [52] J. Z. Xiao, S. Kondo, N. Yanagisawa et al., “Effect of probiotic *Bifidobacterium longum*
671 BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of
672 Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-
673 controlled trial,” *Journal of Investigational Allergology & Clinical Immunology*, vol. 16, no.
674 2, pp. 86-93, 2006.
- 675 [53] J. Z. Xiao, S. Kondo, N. Yanagisawa et al., “Clinical efficacy of probiotic
676 *Bifidobacterium longum* for the treatment of symptoms of Japanese Cedar Pollen allergy in
677 subjects evaluated in an environmental exposure unit,” *Allergology International*, vol. 56,
678 no.1, pp. 67-75, 2007.
- 679 [54] L. Z. Xu, L. T. Yang, S. Q. Qiu et al., “Combination of specific allergen and probiotics
680 induces specific regulatory B cells and enhances specific immunotherapy effect on allergic
681 rhinitis,” *Oncotarget*, vol. 7, no. 34, pp. 54360-54369, 2016, doi: 10.18632/oncotarget.10946.
- 682 [55] S. Yonekura, Y. Okamoto, T. Okawa et al., “Effects of daily intake of *Lactobacillus*
683 *paracasei* strain KW3110 on Japanese cedar pollinosis,” *Allergy & Asthma Proceedings*, vol.
684 30, no. 4, pp. 397-405, 2009, doi: 10.2500/aap.2009.30.3256.
- 685 [56] C. Cingi, M. Conk-Dalay, H. Cakli, and C. Bal, “The effects of spirulina on allergic
686 rhinitis,” *European Archives of Otorhinolaryngology*, vol. 265, no. 10, pp. 1219-23, 2008
687 doi: 10.1007/s00405-008-0642-8.
- 688 [57] M. Yoshimura, T. Enomoto, Y. Dake et al., “An evaluation of the clinical efficacy of
689 tomato extract for perennial allergic rhinitis,” *Allergology International*, 56(3):225-230,
690 2007.
- 691 [58] S. Friedlander and S. M. Feinberg, “Vitamin C in hay fever: therapy and blood levels,”
692 *The Journal of Allergy & Clinical Immunology*, vol. 16, no. 3, pp. 140–145, 1945, doi:
693 [https://doi.org/10.1016/0021-8707\(45\)90353-4](https://doi.org/10.1016/0021-8707(45)90353-4).

- 694 [59] H. N. Holmes and W. Alexander, "Hay fever and vitamin C," *Science*; vol. 96, p. 497,
695 1942.
- 696 [60] L. Podoshin, R. Gertner and M. Fradis, "Treatment of perennial allergic rhinitis with
697 ascorbic acid solution," *Ear Nose Throat Journal*, vol. 70, no. 1, pp. 54-5, 1991.
- 698 [61] S. L. Ruskin, "The use of cevitamic acid in the symptomatic and coseasonal treatment of
699 pollinosis," *Annals of Allergy*, vol. 7, no. 1, pp. 65-70, 1949.
- 700 [62] C. Vollbracht, M. Raithel, B. Krick, K. Kraft, and A. F. Hagel, "Intravenous vitamin C
701 in the treatment of allergies: an interim subgroup analysis of a long-term observational
702 study," *Journal of Internal Medicine Research*, vol. 46, no. 9, pp. 3640-3655, 2018, doi:
703 10.1177/0300060518777044.
- 704 [63] J. Jerzyńska, W. Stelmach, B. Rychlik et al., "Clinical and immunological effects of
705 vitamin D supplementation during the pollen season in children with allergic rhinitis,"
706 *Archives of Medical Science*, vol. 14, no. 1, pp. 122-131, 2018, doi:
707 10.5114/aoms.2016.61978.
- 708 [64] A. Malik, B. Menon, Y. Dar et al., "Placebo controlled trial of vitamin D
709 supplementation in allergic rhinitis," *European Respiratory Journal*, vol. 46, suppl. 59,
710 PA2559, 2015, doi: 10.1183/13993003.congress-2015.PA2559.
- 711 [65] B. Z. Rappaport, C. I. Reed, M. L. Hathaway, and H. C. Struck, "The treatment of hay
712 fever and asthma with viosterol of high potency," *Journal of Allergy*, vol. 5, no. 6, pp. 541-
713 553, 1934.
- 714 [66] R. Ariano, "Efficacy of a novel food supplement in the relief of the signs and symptoms
715 of seasonal allergic rhinitis and in the reduction of the consumption of anti-allergic drugs,"
716 *Acta Biomedica*, vol. 86, no. 1, pp. 53-58, 2015.
- 717 [67] G. Ciprandi and A. Varricchio, "Vitamin D3 plus *Lactobacillus reuteri* DSM 17938 as
718 adjuvant for allergen immunotherapy: A preliminary experience," *Jacobs Journal of Allergy
719 & Immunology*, vol. 2, no. 2, p. 014, 2015.
- 720 [68] B. B. Montaña Velázquez, K. Jáuregui-Renaud, C. Bañuelos Arias Adel et al., "Vitamin
721 E effects on nasal symptoms and serum specific IgE levels in patients with perennial allergic
722 rhinitis," *Annals of Allergy, Asthma & Immunology*, vol. 96, no. 1, pp. 45-50, 2006.
- 723 [69] E. Shahaar, G. Hassoun, and S. Pollack, "Effect of vitamin E supplementation on the
724 regular treatment of seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*,
725 vol. 92, no. 6, pp. 654-658, 2004.
- 726 [70] M. C. Denis, A. Furtos, S. Dudonné, et al., "Apple peel polyphenols and their beneficial
727 actions on oxidative stress and inflammation," *PloS One*, vol. 8, no. 1, e53725, 2013.
728 doi:10.1371/journal.pone.0053725.
- 729 [71] J. Wruss, P. Lanzerstorfer, S. Huemer et al., "Differences in pharmacokinetics of apple
730 polyphenols after standardized oral consumption of unprocessed apple juice," *Nutrition
731 Journal*, vol 14, p. 32, 2015, doi:10.1186/s12937-015-0018-z.

- 732 [72] S. R. Yende, U. N. Harle, B. B. Chaugule, “Therapeutic potential and health benefits of
733 Sargassum species,” *Pharmacognosy Reviews*, vol. 8, no. 15, pp. 1–7, 2014,
734 doi:10.4103/0973-7847.125514.
- 735 [73] H. Yoshioka, M. Ishida, K. Nishi et al., “Studies on anti-allergic activity of Sargassum
736 horneri extract,” *Journal of Functional Foods*, vol. 10, no. 2014, pp. 154-160, 2014,
737 https://doi.org/10.1016/j.jff.2014.06.002.
- 738 [74] S. Benjamin, P. Prakasan, S. Sreedharan, A. D. Wright, and F. Spener, “Pros and cons of
739 CLA consumption: an insight from clinical evidences,” *Nutrition & Metabolism*, vol. 12, p. 4,
740 2015, doi:10.1186/1743-7075-12-4.
- 741 [75] M. G. Miguel, M. D. Antunes, and M. L. Faleiro, “Honey as a complementary
742 medicine,” *Integrative Medicine Insights*, vol. 12, 1178633717702869, 2017,
743 doi:10.1177/1178633717702869.
- 744 [76] J. Mlcek, T. Jurikova, S. Skrovankova, and J. Sochor, “Quercetin and its anti-allergic
745 immune response,” *Molecules*, vol. 21, no. 5, p. 623, 2016, doi:10.3390/molecules21050623.
- 746 [77] M. Butawan, R.L. Benjamin, and R. J. Bloomer, “Methylsulfonylmethane: applications
747 and safety of a novel dietary supplement,” *Nutrients*, vol. 9, no. 3, p. 290, 2017,
748 doi:10.3390/nu9030290.
- 749 [78] P. Markowiak and K. Śliżewska, “Effects of probiotics, prebiotics, and synbiotics on
750 human health,” *Nutrients*; vol. 9, no. 9, p. 1021, 2017, doi:10.3390/nu9091021.
- 751 [79] A. Finamore, M. Palmery, S. Bensehaila, and I. Peluso, “Antioxidant,
752 immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly
753 spirulina,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, 3247528, 2017.
754 doi:10.1155/2017/3247528.
- 755 [80] P. D. Karkos, S. C. Leong, C. D. Karkos, N. Sivaji, and D. A. Assimakopoulos,
756 “Spirulina in clinical practice: evidence-based human applications,” *Evidence-Based
757 Complementary and Alternative Medicine*, vol. 2011, 531053, 2011.
758 doi:10.1093/ecam/nen058.
- 759 [81] A. Raiola, M. M. Rigano, R. Calafiore, L. Frusciante, and A. Barone, “Enhancing the
760 health-promoting effects of tomato fruit for biofortified food,” *Mediators of Inflammation*,
761 vol. 2014, 139873, 2014, doi:10.1155/2014/139873.
- 762 [82] B. Chauhan, M. Gupta, and K. Chauhan, “Role of antioxidants on the clinical outcome
763 of patients with perennial allergic rhinitis,” *Allergy & Rhinology (Providence, R.I.)*, vol. 7,
764 no. 2, pp. 74–81, 2016, doi:10.2500/ar.2016.7.0163.
- 765 [83] H. M. Seo, Y. H. Kim, J. H. Lee et al., “Serum zinc status and its association with
766 allergic sensitization: The Fifth Korea National Health and Nutrition Examination Survey,”
767 *Scientific Reports*, vol. 7, no. 1, p. 12637, 2017, doi:10.1038/s41598-017-13068-x.

- 768 [84] Y-Y. Han, B. Blatter, J. M., Brehm et al., “Diet and asthma: vitamins and methyl
769 donors,” *The Lancet. Respiratory Medicine*, vol. 1, no. 10, pp. 813-822, 2013,
770 doi:https://doi.org/10.1016/S2213-2600(13)70126-7.
- 771 [85] H. Q. Tian and L. Cheng, “The role of vitamin D in allergic rhinitis” *Asia Pacific
772 Allergy*, vol. 7, no. 2, pp. 65-73, 2017, doi: 10.5415/apallergy.2017.7.2.65.
- 773 [86] H. Mirzakhani, A. Al-Garawi, S. T. Weiss, and A. A. Litonjua, “Vitamin D and the
774 development of allergic disease: how important is it?,” *Clinical and Experimental Allergy*,
775 vol. 45, no. 1, pp. 114–125, 2015, doi:10.1111/cea.12430.
- 776 [87] M. Asif, “Health effects of omega-3,6,9 fatty acids: Perilla frutescens is a good example
777 of plant oils,” *Oriental Pharmacy and Experimental Medicine*, vol. 11, no. 1, pp. 51–59,
778 2011, doi:10.1007/s13596-011-0002-x.
- 779 [88] A. L. Caraffa, G. Varvara, E. Spinassos et al., “Is vitamin E an anti-allergic compound?,”
780 *Journal of Biological Regulators & Homeostatic Agents*, vol. 30, no. 1, pp. 11-15, 2016.
- 781 [89] C. A. Stone Jr., J. Cook-Mills, T. Gebretsadik et al., “Delineation of the individual
782 effects of vitamin E isoforms on early life incident wheezing,” *The Journal of Pediatrics*, vol.
783 206, pp 156-163.e3, 2019. doi: 10.1016/j.jpeds.2018.10.045.
- 784 [90] G. Yang, Z. Q. Liu, and P. C. Yang, “Treatment of allergic rhinitis with probiotics: an
785 alternative approach,” *North American Journal of Medical Science*, vol. 5, no. 8, pp. 465-
786 468, 2013, doi: 10.4103/1947-2714.117299.
- 787 [91] T. J. Newman, “Local, unpasteurized honey as a treatment for allergic rhinitis: a
788 systematic review,” *School of Physician Assistant Studies*, Paper 462, 2014.
- 789 [92] M. Ronis, K. B. Pedersen, and J. Watt, “Adverse effects of nutraceuticals and dietary
790 supplements,” *Annual Review of Pharmacology and Toxicology*; 58: 583–601, 2018,
791 doi:10.1146/annurev-pharmtox-010617-052844.
- 792 [93] K. F. Schulz, D. G. Altman, and D. Moher, “CONSORT 2010 statement: Updated
793 guidelines for reporting parallel group randomised trials,” *BMJ*, vol. 340, pp. 698–702, 2010,
794 doi: 10.1136/bmj.c332.
- 795 [94] E. von Elm, D. G. Altman, and M. Egger, “The strengthening the reporting of
796 observational studies in epidemiology (STROBE) statement. guidelines for reporting
797 observational studies,” *Epidemiology*, vol. 18, pp. 800–804, 2007, doi:
798 10.1136/bmj.39335.541782.AD.
- 799 [95] N. L. Leech, and A. J. Onwuegbuzie, “Guidelines for conducting and reporting mixed
800 research in the field of counseling and beyond,” *Journal of Counseling & Development*, vol.
801 88, pp. 61–69, 2010, doi: 10.1002/j.1556-6678.2010.tb00151.x.
- 802 [96] R. Chafe, “The value of qualitative description in health services and policy research.
803 Valeur de la description qualitative dans la recherche sur les politiques et services de santé,”
804 *Healthcare Policy = Politiques de sante* vol. 12, issue 3, pp. 12–18, 2017.